お知らせ • Oct 19
Albert Labs International Corp. Appoints Shabir Hasham to Its Board of Directors Albert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals. Board Change • Sep 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Sep 07
Albert Labs International Corp. Announces CEO Changes Albert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found. お知らせ • Sep 06
Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of Directors Albert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found. Board Change • Aug 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 11
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.